Analysts Are Bullish on These Healthcare Stocks: Stemline Therapeutics Inc (STML), Alimera (ALIM)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Stemline Therapeutics Inc (STMLResearch Report), Alimera (ALIMResearch Report) and Immunomedics (IMMUResearch Report) with bullish sentiments.

Stemline Therapeutics Inc (STML)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Stemline Therapeutics Inc today and set a price target of $35.00. The company’s shares closed last Monday at $10.94.

According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -14.1% and a 24.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and Turning Point Therapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Stemline Therapeutics Inc with a $27.25 average price target, representing a 154.2% upside. In a report issued on September 18, Cowen & Co. also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

Alimera (ALIM)

B.Riley FBR analyst Andrew D’silva assigned a Buy rating to Alimera today and set a price target of $2.00. The company’s shares closed last Monday at $0.53.

According to TipRanks.com, D’silva is a 2-star analyst with an average return of -0.1% and a 37.2% success rate. D’silva covers the Healthcare sector, focusing on stocks such as Cumberland Pharmaceuticals Inc, EyePoint Pharmaceuticals Inc, and Eton Pharmaceuticals Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alimera with a $1.75 average price target.

Immunomedics (IMMU)

B.Riley FBR analyst Harshita Polishetty reiterated a Buy rating on Immunomedics today and set a price target of $28.00. The company’s shares closed last Monday at $14.32.

According to TipRanks.com, Polishetty is a 4-star analyst with an average return of 16.8% and a 46.2% success rate. Polishetty covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Karyopharm Therapeutics.

Currently, the analyst consensus on Immunomedics is a Strong Buy with an average price target of $25.67, a 79.4% upside from current levels. In a report released yesterday, Cowen & Co. also maintained a Buy rating on the stock with a $30.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.